Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019


Phacilitate Leaders Europe Agenda 2018


Patient advocacy collaboration needs: breaking down barriers in patient access to secure success for cell and gene therapies in the real world

12 Sep 2018
  • The perfect collaboration: How do you create a strong relationship with patient advocacies?
  • What is need to know for the patient about ATMPs? Can the field do more to educate these patients- if so what is the best way to approach this?
  • What are patient advocacies expectations from  pharma/biotech/academia in the R&D setting? What is the best package the cell and gene therapy industry can bring to the patient to ensure the therapy is brought to market faster?
  • What information do they expect from the regulatory authorities?
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd